Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients

Stock Information for Revelation Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Revelation Biosciences Inc.

Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds
Revelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical Data
Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data
Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025
Revelation Biosciences, Inc. Congratulates Its Former Chairman of the Board, George Tidmarsh, on His Appointment as the Head of the FDA Center for Drug Evaluation and Research
Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study
Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.